Comparative Efficacy of Infliximab vs Ustekinumab for Maintenance of Clinical Response in Biologic Naïve Crohn's Disease.
Emily C L WongParambir S DulaiJohn K MarshallVipul JairathWalter ReinischNeeraj NarulaPublished in: Inflammatory bowel diseases (2022)
Treatment with infliximab and ustekinumab among induction responders achieved 1-year CR with similar efficacy, but infliximab may confer greater benefit for endoscopic outcomes. Findings should be interpreted with caution as our analyses were unpowered.